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Setting: Patients HIV+ attending in a reference clinic, Southern Brazil.
Objective: To compare the interferon-gamma-release assay (IGRA – QuantiFERON® TB Gold
In-Tube) with the tuberculin skin test (TST – PPD-Rt 23) for latent tuberculosis infection (LTBI)
in  patients with HIV.
Design: Cohort study. Patients were simultaneously submitted to the TST and blood collec-
tion for the IGRA.
Results: A total of 140 subjects were included. Nine (6.4%) were IGRA+/TST+, 12 (8.6%) were
IGRA+/TST−,  4 (3%) were IGRA−/TST+, and 115 (82%) IGRA−/TST−. There was poor agree-
ment between tests (kappa = 0.2), and no correlation between these results and CD4+ T
lymphocyte counts. During follow-up, one patient with negative results on both tests died
from sepsis, and another with discordant results (IGRA+/TST−) exhibited TST serocon-
version. Compared to the TST, IGRA showed a sensitivity and speciﬁcity of 69% and 90%,
respectively. The IGRA detected 8% more positive results than the TST. All patients were
followed up for 2 years.
Conclusion: The higher accuracy of the IGRA would result in LTBI treatments being admin-ho wistered to patients wactive tuberculosis cases. 
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.ould have otherwise been overlooked, decreasing the number ofThe long-term survival of HIV carriers requires further evaluation.
© 2015 Elsevier Editora Ltda. All rights reserved.
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Introduction
In 2012, approximately 8.6 million people worldwide devel-
oped tuberculosis (TB),1–3 with the majority occurring in Asia
(55%) and Africa (30%).4,5 Brazil is among the 22 countries
with high TB burden; in 2012, 70,000 new cases of TB were
detected in Brazil and approximately 4600 patients died of the
disease. In Paraná State the incidence of tuberculosis is 22 for
every 100,000 inhabitants. In addition, HIV/TB co-infection is
the main cause of death with deﬁned etiology among AIDS
patients.4–6 Preliminary data from the Brazilian Ministry of
Health show an average of 9.7% of HIV/TB co-infection; the
rate is highest in the state of Rio Grande do Sul in Southern
Brazil at approximately 19%.7,8
One of the main tasks of the Stop TB Partnership project,
which aims to control the worldwide impact of TB, is more
rapid detection and treatment of latent TB infection (LTBI),
particularly in HIV-positive patients.5 Latent infection occurs
through initial ﬁrst contact with Mycobacterium tuberculosis
and has no signs of active infection. At this stage, the tuber-
culin skin test (TST) can detect an immune response against
the microorganisms that may persist throughout a person’s
lifetime.6 However, there is a risk of disease reactivation,
which occurs in 2–23% of immunocompetent patients and
at a rate of least 10% per year in immunocompromised
individuals.6,9 LTBI treatment with isoniazid monotherapy can
reduce the possibility of active disease progression and is rec-
ommended for patients with risk factors such as HIV and
immunosuppressive drug treatment.10,11
The TST is a widely used immunodiagnostic test for LTBI
detection.9 However, this technique has several disadvantages
such as false-positive results in vaccinated individuals9,12–15;
many lost readings14–16; false-negative results in individuals
with recent active TB, malnutrition, congenital immunode-
ﬁciency, malignant neoplasms, disseminated TB, systemic
viral diseases, live-virus vaccines, and immunosuppression
(e.g., patients with HIV with CD4+ T lymphocyte counts
<400 cells/mm3)12,17; and errors in technical implementation
and/or reading of the results.16,18,19
In vitro interferon-gamma (IFN-) release assays (IGRAs)
are an alternative for detecting LTBI that have become a
widespread mainly in developed countries, which have low TB
prevalence.9,20,21 IGRAs are based on measuring IFN- released
from CD4+ T lymphocytes upon stimulation by M.  tuberculosis-
speciﬁc antigens.21 Two commercial IGRAs are currently
available: QuantiFERON® TB Gold In-Tube (Cellestis Limited,
Victoria, Australia), which is based on an enzyme immunoas-
say, and the T-SPOT®.TB test (T-Spot; Oxford Immunotec,
Abingdon, UK), which detects the numbers of IFN--producing
cells represented as spot-forming units.22 IFN- release indi-
cates the presence of TB infection either latent or disease.2
Unlike the TST, neither Bacillus Calmette-Guérin vaccine
nor infection by non-TB mycobacteria interferes with IGRA
results.23
Despite the importance of the detection and treatment of
LTBI to control TB in developing countries, few studies have
evaluated the performance of IGRA testing in HIV-infected
patients in countries with high TB incidence. Therefore, this 0 1 6;2  0(1):69–75
study compared the ability of the IGRA with the TST to detect
LTBI in a cohort of patients with HIV and determined the cor-
relations between test results and outcomes.
Materials  and  methods
Study  population
This was a prospective non-randomized cohort study con-
ducted from August 2012 to August 2014 in a tertiary
care academic center, Hospital de Clínicas/Universidade
Federal do Paraná (HC/UFPR) in Curitiba, Southern Brazil.
The Institutional Review Board approved this study (IRB:
#02239612.4.0000.0096), and all included patients provided
written informed consent.
Sample size calculation was based on an  ˛ error of 0.05
and  ˇ error of 0.10 (90% power). For these calculations, the dis-
cordance rate between the TST and IGRA was arbitrarily set
at 30%. Considering that there were approximately 1400 HIV-
positive patients treated at this hospital, a ﬁnite population
correction factor was used to reduce the standard error. Incor-
porating these estimates into the equation yielded a sample
size of 100. A total of 154 patients were enrolled.
Outpatients aged >18 years who attended the HIV reference
clinics at HC/UFPR were invited to participate in this study.
Patients currently undergoing chemoprophylaxis or treatment
for TB and those with recent TST results were excluded.
A standardized form was created for data collection, which
included patient demographic, laboratory, and clinical infor-
mation.
Participants were simultaneously submitted ﬁrst to the
venous blood collection for the IGRA and then to the TST.
To exclude active TB, all HIV-positive patients with a positive
TST result (>5 mm)  underwent chest radiography and sputum
specimen analysis by acid-fast bacilli smear and culture. In
excluded active disease cases, isoniazid was administered for
6 months.11,24 Chemoprophylaxis was not recommended for
patients with negative TST results regardless of IGRA results
according to the Brazilian guideline at the time of the study.4
CD4+ T lymphocyte counts were determined in all patients
by ﬂow cytometry with FACScaliburTM (Becton Dickinson Inc.,
San Jose, CA, USA) and the Point-Of-Care CD4 Alere PimaTM
(Alere, Germany).
IGRA
QuantiFERON® TB Gold In-Tube (Cellestis Limited, Victoria,
Australia) was used according to the manufacturer’s instruc-
tions. The results were interpreted using speciﬁc software
provided by the manufacturer. A result was considered pos-
itive if there was IFN- production in the test tube indicated
by an optical density ≥0.35 IU/mL and ≥25% of that in the
negative control tube. An indeterminate result was deﬁned as
low mitogen response (<0.5 IU/mL), if the negative control tube
showed an optical density >8 IU/mL, or if the test tube optical
density was <0.35 IU/mL or <25% of that of the negative control
tube.
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ssay; TST, tuberculin skin test.
ST
he TST was carried out by intradermal administration of
.1 mL  PPD-Rt 23 (Staten Serum Institute, Copenhagen, Den-
ark) to the anterior portion of the left forearm. The results
ere collected after 48–72 h. The transverse diameter of TST
nduration was measured by a ruler, and readings ≥5 mm were
onsidered positive reactions. The same qualiﬁed professional
erformed all TSTs and readings.
ata  analysis
ata were compiled using JMP  version 5.2.1 (SAS Insti-
ute Inc., Cary, NC, USA) and analyzed using GraphPad
rism version 5.03 (GraphPad Software Inc., La Jolla, CA,
SA). Baseline demographic and clinical characteristics with
ormal and non-normal distributions are presented as
eans ± standard deviation and medians with interquartile
anges (IQRs), respectively. Fisher exact test, Student t-test, or
he Mann–Whitney U-test was used where appropriate. All p-
alues are based on two-tailed comparisons, and the level of
igniﬁcance was set at p < 0.05.
The operational characteristics and 95% conﬁdence inter-
als (CIs) of the IGRA were calculated considering the TST
s the gold standard. Cohen kappa coefﬁcient was used
o assess the degree of concordance between tests. The
trength of agreement was considered poor, fair, moderate,
ubstantial, and optimal for kappa values ≤0.20, 0.21–0.40,
.41–0.60, 0.61–0.80, and 0.81–1.0, respectively.24 The correla-
ion between tests was assessed by Spearman correlation.esults
 total of 154 patients were enrolled. Among them, 14 (9%) did
ot return for the tuberculin test reading. One hundred ﬁfteen numbers obtained for ﬁnal analysis. IGRA, IFN- release
(82%) patients had negative results on both tests. Discordant
results were observed in 16 (11%) patients including 4 with
positive TST and negative IGRA results, and 12 with negative
TST and positive IGRA results. There was no statistical evi-
dence that either method was different, because the rates of
discrepancies were not signiﬁcantly different (Fig. 1) (p = 0.08).
Thirteen (9%) patients were diagnosed with LTBI on the
basis of TST results, and isoniazid was administered for 6
months, with 100% adherence to the treatment. Considering
the TST and IGRA results, a total of 25 (17%) patients presented
with LTBI; thus, the IGRA detected 8% more  cases (95% CI,
7.9–8.16%, p = 0.0363). Patients with only positive IGRA results
were not treated and are currently in follow-up.
The patients were classiﬁed into 4 groups according to
concordant and discordant results. Table 1 shows the epidemi-
ological and clinical data from patients stratiﬁed according to
the 4 combinations of TST and IGRA results.
The assay results were related to CD4+ T cell count,
and TST-positive results were detected only in patients with
a CD4+ T lymphocyte count >300 cells/mm3, while IGRA-
positive results were observed in patients with low CD4+
T lymphocyte counts. However, only 21.5% of the studied
patients had CD4+ T lymphocyte counts <300 cells/mm3.
There was no inﬂuence of the presence of BCG vaccina-
tion in any of the two tests, but it should be noted that
most patients were vaccinated in infancy (109/140–77.8%), i.e.,
immune stimulation occurred many  years, which may have
contributed to this ﬁnding.
Among the patients included in this study there was fre-
quent reports of contact with people with TB, though most
were asymptomatic, this should be seen as a warning sign
to the physician who is performing the monitoring of this
patient, as exposure to TB is a criteria to recommended LTBI
treatment, regardless of TST results.
To investigate the relationship between the immune
response against antigenic stimulation, the correlation
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Table 1 – Demographic, epidemiological, and clinical characteristics of study patients according to IGRA and TST results
(N = 140).
Group 1 Group 2 Group 3 Group 4 p
TST−/IGRA− TST+/IGRA+ TST−/IGRA+ TST+/IGRA−
n = 115 n = 09 n = 12 n = 04
Sex 0.0977
Female 55 6 8 4
Male 60 3 4 0
Age (years) 45.1 38.9 40.1 52.3 0.4125
Median (IQR) (36.9–52.7) (32.1–50.6) (31.4–49.4) (43.8–66.3)
Contact with TB 0.0076
No 94 3 8 3
Yes 21 6 4 1
Cough 0.8524
No 99 8 11 3
Yes 16 1 1 1
BCG vaccine 0.5682
No 25 2 2 2
Yes 90 7 10 2
Length of HIV diagnosis (years),
Median (IQR)
10.1
(4.7–13.7)
7.1
(6.7–9.0)
9.9
(5.3–16.3)
13
(5.5–22.8)
0.5047
Nadir  CD4+ TL
(cells/mm3)
145
(33–303)
272
(219–317)
198.5
(120.7–304.7)
228
(61.7–290.7)
0.1493
Median (IQR)
Current CD4+ TL
(cells/mm3)
496
(282–705)
484
(441.5–916.5)
492.5
(307.8–835.8)
515
(396.5–638.7)
0.6241
Median (IQR)
Opportunistic disease 0.42
No 81 8 10 2
Yes 34 1 2 2
HIV viral load NA
Detectable/undetectable 34/81 1/8 8/4 0/4
Antiretroviral treatment NA
No 17 1 1 0
Yes 98 8 11 4
IGRA, interferon-gamma release assay; TST, tuberculin skin test; BCG, Bacillus Calmette-Guérin; TB, tuberculosis; LTBI, latent tuberculosis
omeginfection; CDC, Centers for Disease Control and Prevention; CMV, cyt
between TST results (in mm),  and the current CD4+ T lympho-
cyte counts was analyzed (Fig. 2A). In addition, the correlation
between optical absorbance values obtained in the IGRA and
current CD4+ T lymphocyte counts was evaluated (Fig. 2B).
However, no correlations were detected.The agreement between the TST and IGRA was assessed
using the Cohen kappa coefﬁcient, which was found to be
0.214, indicating poor concordance. Considering TST results
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Fig. 2 – Correlations between TST (A) and IGRA (B) ralovirus; IQR, interquartile range; TL, T lymphocyte.
as the gold standard for LTBI diagnosis, the IGRA test per-
formance was calculated: the sensitivity and speciﬁcity were
69% and 90%, respectively. To calculate the positive and nega-
tive predictive values, different prevalence of TB (2–15%) were
evaluated; as expected, the positive predictive value varied
considerably (Table 2) (Fig. 3).
All patients were followed up for 2 years. One patient
with negative results in both tests died from sepsis. Another
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Table 2 – IGRA performance characteristics with respect
to TB prevalence.
Performance
characteristics
TB  prevalence IGRA
Sensitivity – 69% (95% CI, 42–87%)
Speciﬁcity – 90% (95% CI, 84–94%)
PPV 2% 12%
NPV 99%
+LR 0.14
−LR 0.007
PPV 10% 43%
NPV 96%
+LR 0.76
−LR 0.38
PPV 15% 55%
NPV 94%
+LR 1.2
−LR 0.06
p
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F
pPPV, positive predictive value; NPV, negative predictive value; +LR,
positive likelihood ratio; −LR, negative likelihood ratio.
atient with discordant results (TST−/IGRA+) presented with
ST seroconversion and was started on chemoprophylaxis.
here were no cases of active TB.
iscussion
ost studies that evaluated the performance of the IGRA for
TBI diagnosis were conducted in regions with low disease
revalence and primarily included HIV-negative individuals.
hese studies showed a good correlation between a positive
est result and the presence of LTBI or even active TB.25–27 In
he present study, the performance of the IGRA methodology
as evaluated in HIV-positive patients living in a region with
igh TB prevalence. No patients with low CD4+ T lymphocyte
ounts had positive TST results, highlighting the difﬁculties
f LTBI diagnosis in immunosuppressed patients. On the
ther hand, IGRA results were positive even in patients
ith lower CD4+ T lymphocyte counts despite the smaller
umber of patients. It is important to note that the majority
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ig. 3 – IGRA positive predictive value (PPV) and negative
redictive value (NPV) according to TB prevalence. 1 6;2  0(1):69–75 73
of studied patients (78.5%) had CD4+ T lymphocyte counts
>300 cells/mm3. However, the proportion of IGRA positivity
was similar regardless of CD4+ T lymphocyte count, similar
ﬁndings were reported by Souza et al. (2014).28
Previous report comparing TST and IGRA results showed
poor agreement, indicating that neither test can be used in
place of the other.28 Thus, these methodologies should be used
to complement each other; the method should be selected
depending on patient characteristics. In HIV-positive patients,
the TST should be performed only in individuals with CD4+ T
lymphocyte counts >400 cells/mm3, while the IGRA should be
performed for those who have difﬁculty returning for a second
visit, those recently vaccinated with Bacillus Calmette-Guérin,
or those who recently underwent the TST.24
In this study, considering the results obtained by the TST
and IGRA, the use of both techniques would increase the
detection of LTBI patients from 9% (13 patients) to 17% (25
patients). IGRA and TST together detected an additional 8% of
LTBI cases compared to TST alone. If these ﬁndings were con-
ﬁrmed, promptly administered LTBI treatment would reduce
the number of patients with HIV/TB co-infection. However,
further studies should be conducted to conﬁrm the present
conclusions as well as thoroughly evaluate the ﬁnancial impli-
cations of this double testing protocol given the high cost of
the IGRA.
The Centers for Disease Control guidelines does not recom-
mend routine testing with both the TST and IGRA. However,
the results of both tests can be useful when there are risks
of infection or disease progression, especially in HIV-infected
people or children aged <5 years who are exposed to a patient
with infectious TB.27 On the basis of these ﬁndings, we  empha-
size the importance of the introduction of IGRA in routine
laboratory tests for HIV-positive individuals with negative TST
results, recommendation which was subsequently published
by technical statement from the Brazilian Ministry of Health.29
In contrast to some previous reports,9,30–32 in the present
study, there were no indeterminate results. Among the fac-
tors that may have contributed to this, some authors consider
the importance of technical training, operational care, and
attention to detail during the course of collection, transport,
and handling of clinical specimens, because they can directly
inﬂuence the results.33
Some reports show the IGRA could have better results than
the TST in the identiﬁcation of LTBI in patients with higher
degrees of immunosuppression.23 In this study, the propor-
tion of IGRA-positive results in severely immunocompromised
patients was similar to that regarding TST results. However,
the quantitative values (i.e., optical density for the IGRA and
mm in the TST) obtained were not correlated with CD4+ T
lymphocyte counts. It should be noted that the quantiﬁcation
of CD4+ T lymphocytes is just one way to assess cell immune
response in HIV-positive patients. In the present study, no test
was performed to qualitatively evaluate individual immune
responses.
One of the main challenges when evaluating new LTBI diag-
nostic methods is the low sensitivity of the TST as the gold
standard for comparison, which implies difﬁculties on PPV cal-
culating. From regions with low TB prevalence and risk, sensi-
tivity is usually calculated in patients with TB and speciﬁcity
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is measured using clinical data from patients who will be fol-
lowed up and develop TB.34 Furthermore, the evaluation of
these tests requires several individuals as well as prospective
cohort studies comparing the presence of disease among indi-
viduals with positive and negative results over several years.
Compared to the TST, such studies are costly, time consum-
ing, and incur a signiﬁcant risk of loss of patients during
follow-up.
Therefore, this study evaluated the performance charac-
teristics of the IGRA considering the TST as the gold standard.
The sensitivity was 69%, which is similar to that in previous
studies,35,36 and the speciﬁcity was good at 90%. The assess-
ment of the predictive value of the IGRA is impaired, because
LTBI is an asymptomatic infection. However, considering the
distinct prevalence of TB, the IGRA has a low positive predic-
tive value in settings with low TB prevalence, while in areas
with high TB prevalence as secondary reference units, the test
has better positive predictive values. During 2 years of follow-
up, no cases of active TB were detected among the patients
in the present study. Regardless, considering that a patient
with LTBI (i.e., a positive TST result) presents an annual risk
of developing active disease from 5% to 10%,6 a longer follow-
up period is necessary to clarify if a positive IGRA result can
predict progression to TB.
Systematic reviews and meta-analyses have been con-
ducted to evaluate the performance characteristics of the
IGRA. Rangaka et al. (2012) found that neither IGRA nor the TST
has high accuracy for active TB prediction (incidence rate ratio:
2.11 for the IGRA and 1.6 for the TST at a cut-off of 10 mm).35
Moreover, the IGRA positivity rate in countries with high dis-
ease burden and infection rates could indicate M. tuberculosis
sensitization but might not be suitable for predicting TB. Diel
et al. (2011) compared the accuracy of IGRAs with the TST for
LTBI diagnosis and reported a pooled speciﬁcity and negative
predictive value of 99.4% and 94%, respectively.36 Some stud-
ies evaluated the probability of developing active disease (i.e.,
positive predictive value for progression) in individuals with
positive IGRA results, and the rate of progression observed
ranged from 2% to 10%.36
In conclusion, the IGRA can be a complementary tool for
LTBI diagnosis, especially in immunocompromised patients.
The recognition and treatment of LTBI can reduce mor-
bidity and mortality in HIV/TB co-infected patients; these
tests should be performed early regardless of the degree
of immunosuppression. However, the diagnosis of latent M.
tuberculosis infection in people living with HIV/AIDS remains
challenging. The low reactivity of the TST and impact of
HIV/TB co-infection on HIV-positive patient survival highlight
the need for the development and evaluation of new diagnos-
tic methodologies.
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